While BRCAness is known to arise from inactivating mutations or epigenetic silencing of HR-related genes [21, 22], our findings are particularly germane in view of clinical observations that many cancer patients without detectable mutations in genes encoding HR components such as BRCA genes also derive significant clinical benefit from PARP inhibitors [38, 39]. The gene discussed is PARP1; the disease is cancer.